Multivariate analysis showed IPC was not a significant risk factor for cancer-specificsurvival. For the recurrence analysis, stage IV patients were omitted. The recurrence rate was 3/24 (12.5%) in the IPC(+) group versus 6/12 (50%) in the IPC(−) group. This difference was rated significant, despite the small total number ofrecurrences.